Kenvue Inc. (NYSE:KVUE) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 245,885,918 shares of the company's stock after purchasing an additional 8,211,748 shares during the period. Kenvue makes up approximately 0.6% of Price T Rowe Associates Inc. MD's investment portfolio, making the stock its 23rd largest position. Price T Rowe Associates Inc. MD owned 12.82% of Kenvue worth $5,249,665,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in KVUE. Vanguard Group Inc. grew its holdings in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after buying an additional 10,682,003 shares during the period. Geode Capital Management LLC grew its stake in shares of Kenvue by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after acquiring an additional 1,391,854 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Kenvue by 2.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company's stock valued at $533,169,000 after acquiring an additional 561,570 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.19 on Wednesday. The stock's 50-day moving average is $22.97 and its two-hundred day moving average is $22.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a market cap of $44.49 billion, a price-to-earnings ratio of 43.75, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.54%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Citigroup boosted their price objective on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. Barclays reduced their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Finally, Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.